Edition:
United Kingdom

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

33.79USD
7:55pm GMT
Change (% chg)

$5.79 (+20.68%)
Prev Close
$28.00
Open
$28.01
Day's High
$34.11
Day's Low
$27.97
Volume
333,338
Avg. Vol
48,840
52-wk High
$34.11
52-wk Low
$26.43

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $1,144.69
Shares Outstanding(Mil.): 34.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Genomic Health Announces Research Collaboration with Janssen Pharma

* GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT

06 Dec 2017

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

28 Nov 2017

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

08 Nov 2017

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

13 Sep 2017

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

24 Aug 2017

BRIEF-Genomic Health Q2 loss per share $0.08

* Genomic Health announces second quarter 2017 financial results and reports recent business progress

01 Aug 2017

Earnings vs. Estimates